Stoxpo: Harmony Biosciences has shown strong growth with WAKIX. What factors are behind this performance?
Jeffrey Dayno: Our growth is rooted in our commitment to addressing significant unmet needs in neuroscience. WAKIX, as a non-scheduled treatment for excessive daytime sleepiness in adults with narcolepsy, stands out in the market due to its unique mechanism of action. We’ve dedicated significant resources to expanding access, raising awareness, and supporting both patients and healthcare providers, which has strengthened WAKIX’s presence. Additionally, ongoing post-marketing studies and our exploration of WAKIX’s potential in other indications will allow us to help a broader patient community.
Stoxpo: Beyond WAKIX, what’s in Harmony’s pipeline that investors and patients should keep an eye on?
Jeffrey Dayno: We’re especially excited about HBS-102, a drug targeting the melanin-concentrating hormone receptor pathway, which plays a critical role in sleep and other neurological functions. It’s still early in its development, but we see strong promise in HBS-102’s potential to treat additional rare neurological disorders. We’re also continuously looking for partnerships and acquisitions that align with our mission to expand and enhance our portfolio.
Stoxpo: You’ve focused on rare neurological diseases. Do you see further expansion into other areas?
Jeffrey Dayno: While we remain centered on neuroscience and rare, underserved conditions, we’re always open to exploring adjacent opportunities where we can create meaningful impact. With neurological disorders on the rise, particularly those like narcolepsy and central nervous system disorders, we see room for innovation. We plan to stay focused but flexible, building a diverse pipeline that supports patients, caregivers, and the medical community.
Stoxpo: How does Harmony plan to sustain growth and remain competitive?
Jeffrey Dayno: Our strategy is rooted in innovation and patient support. We’re committed to investing in R&D, expanding our commercial reach, and enhancing educational resources for patients and providers. Real-world data helps us refine our approach with WAKIX and sets the foundation for future products. We balance organic growth with strategic M&A to diversify our portfolio and strengthen our position in the market.
Stoxpo: The narcolepsy treatment landscape has seen growth. What sets Harmony apart?
Jeffrey Dayno: Harmony is dedicated to providing safe, effective, and non-scheduled treatment options for narcolepsy. WAKIX’s novel mechanism of action has established it as a trusted treatment in the community. Our focus isn’t only on treating symptoms but also on enhancing quality of life. By consistently seeking feedback from the narcolepsy community, we can address real needs and reinforce WAKIX’s role in narcolepsy care.
Stoxpo: What challenges does Harmony face, and how are you addressing them?
Jeffrey Dayno: One challenge is adapting to potential changes in regulatory standards and market dynamics. To navigate this, we’re expanding our clinical research efforts, engaging proactively with regulatory bodies, and building a robust internal infrastructure. As our pipeline grows, staying focused and rigorous in both development and commercialization is essential to our continued growth and impact.
Stoxpo: How does Harmony’s commitment to patient access factor into its long-term vision?
Jeffrey Dayno: Access is fundamental to Harmony’s mission. We’ve developed programs to assist patients with treatment costs and offer resources to healthcare providers to ease access barriers. Our ultimate aim is to build trust and establish Harmony as a reliable partner to patients, caregivers, and the broader medical community, making meaningful strides in neurological treatment options.
